Advertisement
4D Molecular Therapeutics, Inc. (FDMT)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
At close: 04:00PM EST
After hours:
| Previous Close | 8.83 |
| Open | 8.83 |
| Bid | 8.26 x 100 |
| Ask | 8.35 x 400 |
| Day's Range | 8.19 - 9.18 |
| 52 Week Range | 7.32 - 36.25 |
| Volume | |
| Avg. Volume | 818,517 |
| Market Cap | 432.387M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.24 |
| Earnings Date | Nov 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 49.40 |
GlobeNewswire4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
EMERYVILLE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in November and December and will present at the Ophthalmology Innovation Summit XIV. Members of the management team will also be available
Zacks4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -17.91% and 99.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.